10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares in US biotech Gilead Sciences jumped by 6.7% in morning trading on Wednesday following updates on trials of the investigational antiviral drug remdesivir in severe COVID-19. 29 April 2020
Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, today announced its results for the first quarter 2020 showing strong growth, but still seeing the company’s shares down nearly 3.5% at 185.60 Swedish kronor by close of trading. 29 April 2020
Interleukin (IL)-17A blocker Cosentyx (secukinumab) has picked up a new approval in Europe, for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). 29 April 2020
UK-based Almac Discovery has announced a research tie-up with US pharma giant Merck & Co focusing on the generation of new small molecule inhibitors against specified deubiquitinase (DUB) targets for a range of neurodegenerative and other diseases. 29 April 2020
A novel AXL kinase inhibitor from Norwegian biotech BerGenBio is to be fast-tracked through a new Phase II trial program led by the British government. 29 April 2020
Blueprint Medicines’ shares dropped 19% in early trade on Tuesday and were still down 17.3% at $58.63 at close, after the rare diseases and cancer immunotherapy company announced that its late-stage trial of already marketed Ayvakit (avapritinib) in an extended indication was a flop. 29 April 2020
The National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document (FAD) recommending Stelara for ulcerative colitis. 28 April 2020
US drugmaker Vertex Pharmaceuticals and privately-held Affinia Therapeutics have entered into a strategic research collaboration to engineer adeno-associated virus (AAV) capsids for the delivery of gene therapies. 28 April 2020
New one-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA) showed positive results, according to Swiss pharma giant Roche. 28 April 2020
Shares in Israeli company RedHill Biopharma were 13% higher at the mid-point of Monday’s trading based on an update on the compassionate use program with its investigational drug, Yeliva (opaganib), in six patients with confirmed SARS-CoV-2 infection. 27 April 2020
Partners Sanofi and Regeneron have announced that – following a review by the Independent Data Monitoring Committee (IDMC) – its research work on Kevzara (sarilumab) in COVID-19 will be scaled back. 27 April 2020
The primary endpoint of overall survival (OS) was met in a Phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) that tested positive for PD-L1 in ≥50% of tumor cells. 27 April 2020
Italy’s Italfarmaco Group has provided an update on the clinical development program of givinostat, its proprietary histone deacetylase inhibitor, in Duchenne muscular dystrophy (DMD). 27 April 2020
Osaka-based pharmaceutical firm Shionogi has announced a new project to develop a vaccine for COVID-19, sending shares in the company up over 3% on Monday. 27 April 2020
The latest positive results of the SAkuraStar Study (NCT02073279), a global Phase III clinical study of satralizumab (development code: SA237) have been published in The Lancet Neurology. 27 April 2020
Shares of Swiss biotech firm Santhera Pharmaceuticals were up 26.75% to 10.14 Swiss francs in early trading, after the company announced a COVID-19 related collaboration. 27 April 2020
Like many companies announcing projects targeting COVID-19, German immunotherapeutics specialist BioNTech experienced a share price fillip when it announced plans for a vaccine in March. 24 April 2020
French vaccines major Sanofi has won US Food and Drug Administration approval for a new quadrivalent meningococcal meningitis vaccine, MenQuadfi. 24 April 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024